Strategic asset sale Recent sale of oncology assets to NeoTX/NeoTrail Therapeutics suggests HOOKIPA is refocusing its portfolio. This indicates potential openness to licensing, collaboration, or acquisition discussions for other programs, creating BD opportunities with companies seeking immunotherapy assets or platform capabilities.

Collaborative HBV/HIV focus Gilead collaboration to develop functional cures for HBV and HIV signals a path to partnered development models. For BD outreach, propose co-development, licensing, or milestone-based deals around arenavirus immunotherapies aimed at chronic viral infections and functional cures.

Platform maturity Arenavirus-based immunotherapies form HOOKIPA’s core platform. This offers sales angles around turnkey platform licensing, prototyping of new targets, and rapid-investigator collaborations for other oncology or infectious disease indications.

Financial and market signals Moderate revenue and substantial funding runway (funding of $289M) imply capacity for partnerships or joint venture structures. Approaches could include upfronts plus milestones, option deals, or co-development arrangements to monetize pipeline in the near term.

Leadership and governance shifts Recent executive and board appointments indicate leadership changes and strategic realignment. This can be a strategic moment to initiate executive-level conversations around strategic partnerships, in-licensing opportunities, or portfolio optimization discussions with decision-makers.